To investigate the potential preventive effects of SFK-targeted inhibitors on myofibroblast activation induced by TGF-β, two SFK-inhibitors were employed: dasatinib, an FDA-approved SFK-targeted inhibitor used for chronic myeloid leukemia 36, and NXP900, a novel SRC/YES1-targeted inhibitor with superior selectivity that currently is in clinical trials 37, 38. This evidence concerns the gene YES1 and chronic myelogenous leukemia, BCR-ABL1 positive.